|
|
|
|
|
|
|
|
|
|
Early Oncology Pipeline Data At AACR Annual Meeting
WASHINGTON, April 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from April 6-10. The data reflect Lilly's diverse oncology pipeline via molecules that target several pathways that are among the most common and difficult-to-treat in cancer.
Each of the four molecules―a CDK4/6 inhibitor, MET antibody, MET small molecule and TGF-beta inhibitor―are being evaluated as both single agent tailored therapies and as combination therapies.........
Abstract # LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer. (This preclinical study evaluated the activity of LY2835219 in models of non-small cell lung cancer (NSCLC), melanoma, mantle cell lymphoma (MCL), and ovarian cancer.)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.